Overview

Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
Phase:
Phase 2
Details
Lead Sponsor:
University of Virginia
Treatments:
Lenalidomide
Melphalan
Thalidomide